When do biologic drug patents expire and when will biosimilars launch?

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	KOATE, KOATE-DVI	antihemophilic factor (human)	For Injection	101130	01/24/1974	⤷ Try a Trial	2025-01-04
Baxalta Us Inc.	HEMOFIL M	antihemophilic factor (human)	For Injection	101448	03/14/2001	⤷ Try a Trial	2025-01-04
Grifols Biologicals Llc	ALPHANATE	antihemophilic factor/von willebrand factor complex (human)	For Injection	102475	08/15/1978	⤷ Try a Trial	2025-01-04
Grifols Biologicals Llc	ALPHANATE	antihemophilic factor/von willebrand factor complex (human)	For Injection	102475	06/26/2014	⤷ Try a Trial	2025-01-04
Baxalta Us Inc.	BIOCLATE (ARMOUR), RECOMBINATE	antihemophilic factor (recombinant)	For Injection	103375	12/10/1992	⤷ Try a Trial	2025-01-04
Baxalta Us Inc.	BIOCLATE (ARMOUR), RECOMBINATE	antihemophilic factor (recombinant)	For Injection	103375	03/10/2010	⤷ Try a Trial	2025-01-04
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Title:	Nanoparticles for protein drug delivery
Abstract:	The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one anti-hemophilic factor or bioactive agent characterized with a positive surface charge and their enhanced permeability in oral drug delivery.
Inventor(s):	Sung; Hsing-Wen (Hsinchu, TW), Tu; Hosheng (Newport Beach, CA)
Assignee:	GP Medical, Inc. (Newport Beach, CA) National Tsing Hua University (Hsinchu, TW)
Application Number:	12/378,976
Patent Claims:	see list of patent claims

Patent: 7,897,585